-
Lyles says 'well worth the journey' after winning 100m in Tokyo
-
Nepali duo break own records on Everest
-
North Korean women footballers land in South ahead of rare match
-
North Korean women footballers arrive in South Korea: AFP
-
Rousey demolishes Carano in MMA comeback fight
-
German 'chemical town' fears impact of industrial decline
-
Qantas flight diverted after man bites flight attendant
-
India scrambles to steady rupee as oil shock bites
-
McGregor to make UFC return with Holloway rematch
-
WHO declares international emergency as Ebola outbreak kills more than 80 in DR Congo
-
Crackdown in Southeast Asia pushes scam networks to Sri Lanka
-
'Geek' hangout to tourist draw: Japan's maid cafes
-
Spacecraft to probe how Earth fends off raging solar winds
-
Bulgaria's 'Bangaranga' wins Eurovision, with Israel second
-
Musk wants SpaceX to go public. Here's how it works
-
Big risks and rewards in upcoming IPOs at SpaceX, OpenAI, Anthropic
-
Pal in last duo could ease nerves for PGA leader Smalley
-
Ronaldo suffers more agony as Al Nassr lose 1-0 in AFC final
-
Venezuela expels Maduro ally Alex Saab to US again
-
Rising star Woad in charge at LPGA Queen City Championship
-
Rodgers returning with Steelers for 22nd season
-
Rahm on PGA: 'It's a battle out there'
-
Dara: dancing to victory at Eurovision
-
As U.S. Markets Continue Surging to Historic All-Time Highs, ELEKTROS Believes This Could Be a Defining Opportunity for Penny Stock Investors Seeking Exposure to the Future of Lithium Mining, EV Infrastructure, and Next-Generation Electrification Technologies
-
Napoleon Solo wins 151st Preakness Stakes
-
Last 10 Eurovision winners
-
Smalley grabs PGA lead as wild final day showdown looms
-
Canada cruise passenger 'presumptive positive' for hantavirus
-
Five share PGA lead logjam with wild final day in store
-
Decision time at full-throttle Eurovision final
-
McIlroy charges into the hunt for epic major comeback win
-
Iran confirms squad heading to Turkey for World Cup preparation
-
Bolivian police clash with protesters blocking roads
-
Eurovision final kicks off with Viennese grandeur
-
Svitolina sees off Gauff to win Italian Open, Sinner in men's title showdown
-
Alonso set for appointment as Chelsea manager: reports
-
Spanish star Javier Bardem says 'narrative changing' on Gaza
-
Gujarat miss out on top spot as Kolkata stay alive in IPL
-
Charging McIlroy grabs share of the PGA lead
-
Rwanda genocide suspect Kabuga dead: court
-
No beer for City stars despite FA Cup win, says Guardiola
-
Modi oversees semi-conductor deal on Dutch trip
-
Americans 'should demonstrate like the French,' says Woody Harrelson
-
Vienna abuzz for Eurovision final
-
McFarlane eyes 'massive' Spurs clash after FA Cup final defeat
-
Scuffles from Europe to NYC as Swatch sale descends into chaos
-
Bielle-Biarrey helps Bordeaux-Begles avoid Top 14 slip-up before Champions Cup final
-
Man City still dream of Premier League glory after FA Cup win: Silva
-
Hearts broken as O'Neill summons Celtic's champion spirit
-
'Dance all night': Harry Styles kicks off World Tour in Amsterdam
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
J.Oliveira--AMWN